Poly(ADP-ribose)polymerase 1(PARP1)is a multifunctional protein involved in diverse cellular functions,notably DNA damage repair.Pharmacological inhibition of PARP1 has therapeutic benefits for various pathologies.Des...Poly(ADP-ribose)polymerase 1(PARP1)is a multifunctional protein involved in diverse cellular functions,notably DNA damage repair.Pharmacological inhibition of PARP1 has therapeutic benefits for various pathologies.Despite the increased use of PARP inhibitors,challenges persist in achieving PARP1 selectivity and effective blood-brain barrier(BBB)penetration.The development of a PARP1-specific positron emission tomography(PET)radioligand is crucial for understanding disease biology and performing target occupancy studies,which may aid in the development of PARP1-specific inhibitors.In this study,we leverage the recently identified PARP1 inhibitor,AZD9574,to introduce the design and development of its ^(18)F-isotopologue([^(18)F]AZD9574).Our comprehensive approach,encompassing pharmacological,cellular,autoradiographic,and in vivo PET imaging evaluations in non-human primates,demonstrates the capacity of[^(18)F]AZD9574 to specifically bind to PARP1 and to successfully penetrate the BBB.These findings position[^(18)F]AZD9574 as a viable molecular imaging tool,poised to facilitate the exploration of pathophysiological changes in PARP1 tissue abundance across various diseases.展开更多
基金Steven H.Liang gratefully acknowledges the support provided,in part,by Emory Radiology Chair Fund and Emory School of Medicine Endowed Directorship(USA)James B.Daunais acknowledges the NIH grant support U01AA014106 and AA028007(USA)Jimmy S.Patel is the recipient of NCI cancer biology postdoctoral fellowship(T32CA275777,USA).
文摘Poly(ADP-ribose)polymerase 1(PARP1)is a multifunctional protein involved in diverse cellular functions,notably DNA damage repair.Pharmacological inhibition of PARP1 has therapeutic benefits for various pathologies.Despite the increased use of PARP inhibitors,challenges persist in achieving PARP1 selectivity and effective blood-brain barrier(BBB)penetration.The development of a PARP1-specific positron emission tomography(PET)radioligand is crucial for understanding disease biology and performing target occupancy studies,which may aid in the development of PARP1-specific inhibitors.In this study,we leverage the recently identified PARP1 inhibitor,AZD9574,to introduce the design and development of its ^(18)F-isotopologue([^(18)F]AZD9574).Our comprehensive approach,encompassing pharmacological,cellular,autoradiographic,and in vivo PET imaging evaluations in non-human primates,demonstrates the capacity of[^(18)F]AZD9574 to specifically bind to PARP1 and to successfully penetrate the BBB.These findings position[^(18)F]AZD9574 as a viable molecular imaging tool,poised to facilitate the exploration of pathophysiological changes in PARP1 tissue abundance across various diseases.
